PRR Chart, page-39

Prima BioMed Ltd. (PBMD) Stock Rating Upgraded by Zacks Investment Research

Posted by Scott Moore on Sep 7th, 2016 // No Comments
Prima BioMed Ltd. (NASDAQBMD) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday.
According to Zacks, “Prima Biomed Ltd is a biotechnology company focused on developing oncology therapies in the field of immunotherapy. The Company’s key product candidates in development include CVac, an autologous dendritic cell vaccine for ovarian cancer, monoclonal antibodies for multiple tumor types, and an oral formulation for the Human Papilloma Virus. Prima Biomed Ltd is based in Sydney, Australia. “
A number of other brokerages also recently issued reports on PBMD. Maxim Group restated a “buy” rating on shares of Prima BioMed in a research report on Wednesday, June 8th. FBR & Co restated an “outperform” rating and issued a $6.00 price target on shares of Prima BioMed in a research report on Wednesday, June 15th. HC Wainwright restated a “buy” rating on shares of Prima BioMed in a research report on Wednesday, June 22nd. Finally, Roth Capital restated a “buy” rating and issued a $6.00 price target on shares of Prima BioMed in a research report on Friday, August 26th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Prima BioMed has a consensus rating of “Buy” and an average price target of $4.20.

​

Prima BioMed (NASDAQBMD) opened at 0.8551 on Wednesday. The company’s market cap is $71.65 million. Prima BioMed has a 52 week low of $0.72 and a 52 week high of $1.54. The company has a 50-day moving average of $0.88 and a 200-day moving average of $0.95.
Prima BioMed Limited is an Australia-based biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. The Company focuses on cancer immunotherapy research. The Company’s main pipeline of products is based on the LAG-3 immune control mechanism, which plays a role in the regulation of the T cell immune response.